Immunology

The Global Alliance For Patient Access (GAfPA)’s new white paper on the value of remission in inflammatory rheumatic conditions, discussed during #EULAR2024, outlines that achieving remission is more than just symptom management – it’s also the ability of patients to lead fuller lives in every facet of their care. Click below to read more.

At #EULAR2024, we’re presenting 25 abstracts showcasing data across our #rheumatology portfolio. Learn more about our commitment to delivering solutions for people with immune-mediated diseases: https://bit.ly/3XqF6hI [Video description: Sofie Berg, Pharm.D, Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie, says, “With our rich legacy and understanding of rheumatic diseases, I’m encouraged by the growing body of evidence and long-term data our teams are presenting at EULAR this year as we continue our efforts to advance research in this space.”]

#IBD is a complex set of diseases, meaning patients have diverse needs. Through ongoing research and development, we’re working to find solutions to help them manage their disease. Read how: https://bit.ly/3x1gRfq #UlcerativeColitis #Crohns [Image description: Sofie Berg, Pharm.D., Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie, says, “We are motivated to bring new treatment options to patients in need through our commitment to ongoing research and development in gastroenterology.”]

NEWS: The European Medicines Agency's #CHMP granted a positive opinion for our investigational treatment in #UlcerativeColitis. Read more: https://bit.ly/4bXADY2 #IBD [Video description: On-screen text reads, “Immunology News. Positive CHMP Opinion in Ulcerative Colitis.”]

Landos Biopharma, Inc. is now part of AbbVie. This #acquisition expands our #IBD pipeline and advances our commitment to make a real difference in people’s lives. Learn more: https://bit.ly/3KgBaIW $ABBV [Video description: On-screen text reads, “Landos is now part of AbbVie" followed by the AbbVie and Landos logos.]

Patients are at the heart of everything we do. Our legacy in inflammatory bowel disease (#IBD) and the partnerships we’ve formed with the gastroenterology community have given us insight into the needs of those living with IBD. On #WorldIBDDay, learn more about our work: https://bit.ly/4br7WTu [Video description: Sofie Berg, Pharm.D, Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie, says, “Through innovative research and development, we’re taking bold steps to create solutions that can help patients and physicians be able to set more ambitious treatment goals.”]

Finding the right treatment for people with autoimmune diseases can become a process of trial-and-error costing #patients time, energy and resources. Our #scientists are making big bets in #research to get to the root cause of these diseases. Learn how we’re working to reimagine the standards of care: https://bit.ly/4dGDLsV #WorldIBDDay [Video description: Interviews with two AbbVie employees. On-screen text reads, “This is a story of chasing bold goals no one else has achieved to change many lives. AbbVie presents The Discovery Files: Finding the Molecular Causes of Autoimmune Disease.”]

NEWS: Topline results from our Phase 3b/4 head-to-head study in #AtopicDermatitis announced today. Read more: https://bit.ly/49T1gMp #immunology [Video description: On-screen text reads, “Immunology News.”]

NEWS: Top-line results from our Phase 3 study in #GiantCellArteritis were announced today. Read more: https://bit.ly/49KvuRs #immunology [Video description: On-screen text reads, “Immunology News.”]